Appili Therapeutics Inc.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

7

Website

appilitherapeutics.com

Country

Canada

Exchange

Toronto

Halifax, Canada

Appili Therapeutics Inc., a biopharmaceutical company focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections.

Its portfolio also includes ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis, and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. Incorporated in 2015, the company is headquartered in Halifax, Canada.

Key Stats

52-Week Range

C$0.01C$0.04

Beta-0.21

Trailing P/EN/A

Forward P/E-0.25

Trailing EPS-0.03

Avg Volume

Earnings & Analyst

Next Earnings2026-08-13

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.